We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Institute for Health and Care Excellence issued draft guidance Thursday recommending against routine NHS use of Novartis' Aimovig (erenumab) for preventing migraine. The agency determined that the injectable CGRP receptor antagonist, which co
The Draft Pharma Policy 2017 which was released for comments in mid-August, has an ambitious intent: to make drug pricing ‘more poor oriented while retaining its industry friendliness’.